MedPath

Probiotics in the prevention of lung infection in patients on a ventilator.

Phase 3
Conditions
Health Condition 1: J159- Unspecified bacterial pneumonia
Registration Number
CTRI/2019/04/018659
Lead Sponsor
Fluid researchCMC vellore
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

APatients under department of medicine

BRequiring mechanical ventilation in medical wards, MHDU or MICU for more than 2 day

C Patients relatives are willing to provide informed consent.

Exclusion Criteria

A. Patientâ??s relatives not willing for informed consent.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Ventilator associated pneumonia as defined by CDC guidelinesTimepoint: PATIENT WILL BE ASSESSED DAILY FOR DEVELOPING NEW VENTILATOR ASSOCIATED PNEUMONIA
Secondary Outcome Measures
NameTimeMethod
1 mortality in each admission <br/ ><br>2 3 month mortality <br/ ><br>3 side effects each admission <br/ ><br>4 cost benefit analysis <br/ ><br>Timepoint: 10-30 days;5 no of ventilated days <br/ ><br>6 reintubation ratesTimepoint: 10-30 days;7 duration of ICU stayTimepoint: 10-30 days
© Copyright 2025. All Rights Reserved by MedPath